Announcements Trials
Browse Landscape

Phase

Phase 1 32Phase 2 27Phase 1/2 21Phase NA 8Phase 3 4Phase 2/3 2Phase 4 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 10Other hematologic neoplasm 5CNS 4Head & Neck 3Genitourinary 3Gastrointestinal 3Thoracic 2Myeloid 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 75Lung Neoplasms 48Small Cell Lung Carcinoma 11Neoplasms 10NSCLC 8Colorectal Neoplasms 7Prostatic Neoplasms 6Ovarian Neoplasms 6Brain Neoplasms 6Mesothelioma 5Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Melanoma 4Head and Neck Neoplasms 4Adenocarcinoma of Lung 4Liver Neoplasms 3Hematologic Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Sarcoma 2Recurrence 2Neoplasms by Site 2Neoplasms by Histologic Type 2Multiple Myeloma 2Laryngeal Neoplasms 2

Interventions

Pemetrexed 1Gemcitabine 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Recurrence × Thoracic × Clear all
NCT01774578 2020-05-28

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Lumos Pharma

Phase 2/3 Terminated
135 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02186301 2019-05-07

EGFR

Clovis Oncology, Inc.

Phase 2/3 Terminated
100 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡